Last 12 months
Inside the activity.
0 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2017 Filed Jun 16, 2017 13:29 UTC |
CONRAD HERBERT JDirector
|
GrantCommon Stock, par value $0.001 per share | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-17-009166 · edgar.xml · nonDerivative · entry 1 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,500 F1 · price: On June 15, 2017, the Company awarded 10,000 shares of Company common stock as an annual equity grant in the form of restricted stock awards under the Celldex Therapeutics, Inc. 2008 Stock Option Plan subject to time-based forfeiture restrictions. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 13:29 UTC |
Shoos Karen L.Director
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.32 | $0.00 |
DisclosureSEC source: 0001179110-17-009165 · edgar.xml · derivative · entry 2 LIPTON KAREN SHOOS · CIK 0001255681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-15 F2 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. F3 · derivative.exercise_date: Such option vests in three equal annual installments beginning June 15, 2018. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 13:29 UTC |
Shoos Karen L.Director
|
GrantCommon Stock, par value $0.001 per share | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-17-009165 · edgar.xml · nonDerivative · entry 1 LIPTON KAREN SHOOS · CIK 0001255681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,833 F1 · price: On June 15, 2017, the Company awarded 10,000 shares of Company common stock as an annual equity grant in the form of restricted stock awards under the Celldex Therapeutics, Inc. 2008 Stock Option Plan subject to time-based forfeiture restrictions. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 13:29 UTC |
PENNER HARRY JRDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.32 | $0.00 |
DisclosureSEC source: 0001179110-17-009164 · edgar.xml · derivative · entry 2 PENNER HARRY JR · CIK 0001131148 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-15 F2 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. F3 · derivative.exercise_date: Such option vests in three equal annual installments beginning June 15, 2018. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 13:29 UTC |
PENNER HARRY JRDirector
|
GrantCommon Stock, par value $0.001 per share | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-17-009164 · edgar.xml · nonDerivative · entry 1 PENNER HARRY JR · CIK 0001131148 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,916 F1 · price: On June 15, 2017, the Company awarded 10,000 shares of Company common stock as an annual equity grant in the form of restricted stock awards under the Celldex Therapeutics, Inc. 2008 Stock Option Plan subject to time-based forfeiture restrictions. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 13:29 UTC |
ELLBERGER LARRYDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.32 | $0.00 |
DisclosureSEC source: 0001179110-17-009163 · edgar.xml · derivative · entry 2 ELLBERGER LARRY · CIK 0001219551 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-15 F2 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. F3 · derivative.exercise_date: Such option vests in three equal annual installments beginning June 15, 2018. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 13:29 UTC |
ELLBERGER LARRYDirector
|
GrantCommon Stock, par value $0.001 per share | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-17-009163 · edgar.xml · nonDerivative · entry 1 ELLBERGER LARRY · CIK 0001219551 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,500 F1 · price: On June 15, 2017, the Company awarded 10,000 shares of Company common stock as an annual equity grant in the form of restricted stock awards under the Celldex Therapeutics, Inc. 2008 Stock Option Plan subject to time-based forfeiture restrictions. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 13:28 UTC |
PEPIN RONALDSr. VP & CBO
|
GrantIncentive Stock Option (right to buy) · Derivative | 67,000 | $0.00 Strike: $2.32 | $0.00 |
DisclosureSEC source: 0001179110-17-009159 · edgar.xml · derivative · entry 1 PEPIN RONALD · CIK 0001214504 · Sr. VP & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,000 Underlying: Common Stock · 67,000 shares Expires 2027-06-15 F1 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 15, 2018 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 13:28 UTC |
Cavanaugh SarahSVP of Corp Affairs & Admin.
|
GrantIncentive Stock Option (right to buy) · Derivative | 65,000 | $0.00 Strike: $2.32 | $0.00 |
DisclosureSEC source: 0001179110-17-009160 · edgar.xml · derivative · entry 1 Cavanaugh Sarah · CIK 0001709113 · SVP of Corp Affairs & Admin. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2027-06-15 F1 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 15, 2018 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 13:27 UTC |
Wright Richard M.Sr. VP & CCO
|
GrantIncentive Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $2.32 | $0.00 |
DisclosureSEC source: 0001179110-17-009157 · edgar.xml · derivative · entry 1 Wright Richard M. · CIK 0001646423 · Sr. VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2027-06-15 F1 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 15, 2018 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 13:27 UTC |
Crowley ElizabethSr. VP &CPDO
|
GrantIncentive Stock Option (right to buy) · Derivative | 82,000 | $0.00 Strike: $2.32 | $0.00 |
DisclosureSEC source: 0001179110-17-009156 · edgar.xml · derivative · entry 1 Crowley Elizabeth · CIK 0001681854 · Sr. VP &CPDO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,000 Underlying: Common Stock · 82,000 shares Expires 2027-06-15 F1 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 15, 2018 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 13:26 UTC |
KELER TIBORExecutive VP & CSO
|
GrantIncentive Stock Option (right to buy) · Derivative | 162,000 | $0.00 Strike: $2.32 | $0.00 |
DisclosureSEC source: 0001179110-17-009154 · edgar.xml · derivative · entry 1 KELER TIBOR · CIK 0001429931 · Executive VP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,000 Underlying: Common Stock · 162,000 shares Expires 2027-06-15 F1 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 15, 2018 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 13:27 UTC |
Davis Thomas AndrewExecutive VP & CMO
|
GrantIncentive Stock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $2.32 | $0.00 |
DisclosureSEC source: 0001179110-17-009155 · edgar.xml · derivative · entry 1 Davis Thomas Andrew · CIK 0001338185 · Executive VP & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2027-06-15 F1 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 15, 2018 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 13:26 UTC |
Marucci Anthony SDirector · President & CEO
|
GrantIncentive Stock Option (right to buy) · Derivative | 475,000 | $0.00 Strike: $2.32 | $0.00 |
DisclosureSEC source: 0001179110-17-009153 · edgar.xml · derivative · entry 1 Marucci Anthony S · CIK 0001429933 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 475,000 Underlying: Common Stock · 475,000 shares Expires 2027-06-15 F1 · security: Represents option granted by Issuer pursuant to its 2008 Stock Option and Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 15, 2018 and the remainder vest quarterly (in equal amounts)over the subsequent 12 quarters. Read SEC document |
| June 01, 2017 Filed Jun 1, 2017 12:09 UTC |
McMahon Gerald PhDDirector
|
Tax withholdingCommon Stock, par value $.001 per share | 2,869 | $2.83 | $8,119.27 |
DisclosureSEC source: 0001179110-17-008265 · edgar.xml · nonDerivative · entry 1 McMahon Gerald PhD · CIK 0001290747 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,822 F1 · balance_after: On November 28, 2016, in connection with the Reporting Person's employment separation agreement with Kolltan Pharmaceuticals, Inc., Reporting Person entered into a severance agreement (the "Severance Agreement") with Celldex Therapeutics, Inc. ("Issuer") whereby Issuer agreed to pay Reporting Person 267,356 shares of its common stock, par value $0.001 per share ("Common Stock") less required tax and other withholdings (the "Withholdings"). The Reporting Person previously reported ownership of such 267,356 shares on his Form 3 filed with the Securities and Exchange Commission on December 15, 2016. The shares, less Withholdings, are issuable to Reporting Person in equal monthly installments through December 2018. F2 · balance_after: Pursuant to the Severance Agreement, on June 1, 2017, the Issuer issued 5,485 shares of its Common Stock to the Reporting Person. This Form 4 reflects the disposition to the Issuer of 2,869 shares of its Common Stock to satisfy required Withholdings in connection with such issuance of Common Stock to the Reporting Person. Read SEC document |
| May 01, 2017 Filed May 1, 2017 20:01 UTC |
McMahon Gerald PhDDirector
|
Tax withholdingCommon Stock, par value $.001 per share | 2,869 | $3.33 | $9,553.77 |
DisclosureSEC source: 0001179110-17-006306 · edgar.xml · nonDerivative · entry 1 McMahon Gerald PhD · CIK 0001290747 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,691 F1 · balance_after: On November 28,2016, in connection with the Reporting Person's employment separation agreement with Kolltan Pharmaceuticals, Inc., Reporting Person entered into a severance agreement (the "Severance Agreement") with Celldex Therapeutics, Inc. ("Issuer") whereby Issuer agreed to pay Reporting Person 267,356 shares of its common stock, par value $0.001 per share ("Common Stock") less required tax and other withholdings (the "Withholdings"). The Reporting Person previously reported ownership of such 267,356 shares on his Form 3 filed with the Securities and Exchange Commission on December 15, 2016. The shares, less Withholdings, are issuable to Reporting Person in equal monthly installments through December 2018. F2 · balance_after: Pursuant to the Severance Agreement, on May 1, 2017, the Issuer issued 5,485 shares of its Common Stock to the Reporting Person. This Form 4 reflects the disposition to the Issuer of 2,869 shares of its Common Stock to satisfy required Withholdings in connection with such issuance of Common Stock to the Reporting Person. Read SEC document |
| April 03, 2017 Filed Apr 3, 2017 20:37 UTC |
McMahon Gerald PhDDirector
|
Tax withholdingCommon Stock, par value $.001 per share | 2,869 | $3.61 | $10,357.09 |
DisclosureSEC source: 0001179110-17-005387 · edgar.xml · nonDerivative · entry 1 McMahon Gerald PhD · CIK 0001290747 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,560 F1 · balance_after: On November 28, 2016, in connection with the Reporting Person's employment separation agreement with Kolltan Pharmaceuticals, Inc., Reporting Person entered into a severance agreement (the "Severance Agreement") with Celldex Therapeutics, Inc. ("Issuer") whereby Issuer agreed to pay Reporting Person 267,356 shares of its common stock, par value $0.001 per share ("Common Stock") less required tax and other withholdings (the "Withholdings"). The Reporting Person previously reported ownership of such 267,356 shares on his Form 3 filed with the Securities and Exchange Commission on December 15, 2016. 66,839 shares of Common Stock, less Withholdings were issued to Reporting Person in March 2017 and the remaining 200,517 shares of Common Stock, less Withholdings, are issuable to Reporting Person in equal monthly installments through December 2018. F2 · balance_after: Pursuant to the Severance Agreement, on April 3, 2017, the Issuer issued 5,485 shares of its Common Stock to the Reporting Person. This Form 4 reflects the disposition to the Issuer of 2,869 shares of its Common Stock to satisfy required Withholdings in connection with such issuance of Common Stock to the Reporting Person. Read SEC document |
| March 01, 2017 Filed Mar 1, 2017 21:33 UTC |
MARINO JAMES JDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $3.56 | $0.00 |
DisclosureSEC source: 0001179110-17-003487 · edgar.xml · derivative · entry 1 MARINO JAMES J · CIK 0001198578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2027-03-01 F1 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. F2 · derivative.exercise_date: 100% of the total amount of shares subject to the Option vests on March 1, 2018. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 14:10 UTC |
McMahon Gerald PhDDirector
|
Tax withholdingCommon Stock, par value $.001 per share | 32,927 | $3.54 | $116,561.58 |
DisclosureSEC source: 0001179110-17-003751 · edgar.xml · nonDerivative · entry 1 McMahon Gerald PhD · CIK 0001290747 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,429 F1 · balance_after: On November 28, 2016, in connection with Reporting Person's employment separation with Kolltan Pharmaceuticals, Inc., Reporting Person entered into a severance agreement (the "Severance Agreement") with Celldex Therapeutics, Inc. ("Issuer") whereby Issuer agreed to pay Reporting Person 267,356 shares of its common stock, par value $0.001 per share ("Common Stock") less required tax and other withholdings (the "Withholdings"). 200,517 shares of Common Stock, less Withholdings, will be issued to Reporting Person ratably over 24 months commencing in the first quarter of 2017 and 66,839 shares of Common Stock, less Withholdings will be issued not later than March 15, 2017. The Reporting Person previously reported ownership of such 267,356 shares on his Form 3 filed with the Securities and Exchange Commission on December 15, 2016. F2 · balance_after: Pursuant to the Severance Agreement, on March 1, 2017, the Issuer issued 59,182 shares of its Common Stock to the Reporting Person. This Form 4 reflects the disposition to the Issuer of 32,927 shares of its Common Stock to satisfy required Withholdings in connection with such issuance of Common Stock to the Reporting Person. Read SEC document |
| December 14, 2016 Filed Dec 15, 2016 21:08 UTC |
LaVallee TheresaSVP, Reg.& Precision Medicine
|
GrantIncentive Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $3.72 | $0.00 |
DisclosureSEC source: 0001179110-16-033001 · edgar.xml · derivative · entry 1 LaVallee Theresa · CIK 0001690948 · SVP, Reg.& Precision Medicine 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2026-12-14 F1 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. F2 · derivative.exercise_date: 25% of the total amount of shares subject to the Option vests on December 14, 2017 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters, beginning March 14, 2018. Read SEC document |
| December 14, 2016 Filed Dec 15, 2016 21:08 UTC |
McMahon Gerald PhDDirector
|
GrantNon-Qualified Stock Otion (right to buy) · Derivative | 8,000 | $0.00 Strike: $3.72 | $0.00 |
DisclosureSEC source: 0001179110-16-033000 · edgar.xml · derivative · entry 1 McMahon Gerald PhD · CIK 0001290747 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2026-12-14 F1 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. F2 · derivative.exercise_date: 100% of the total amount of shares subject to the Option vests on December 14, 2017. Read SEC document |
| September 02, 2016 Filed Sep 6, 2016 17:04 UTC |
KELER TIBORExecutive VP & CSO
|
PurchaseCommon Stock, par value $0.001 per share | 3,000 | $3.32 | $9,960.00 |
DisclosureSEC source: 0001179110-16-029306 · edgar.xml · nonDerivative · entry 1 KELER TIBOR · CIK 0001429931 · Executive VP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,868 Read SEC document |
| September 02, 2016 Filed Sep 7, 2016 16:59 UTC |
CATLIN AVERY WSr. VP & CFO
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001179110-16-029382 · edgar.xml · derivative · entry 2 CATLIN AVERY W · CIK 0001255348 · Sr. VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 10,000 shares Expires 2021-08-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: As of August 5, 2015, the option is fully vested. Read SEC document |
| September 02, 2016 Filed Sep 7, 2016 16:59 UTC |
CATLIN AVERY WSr. VP & CFO
|
Exercise / conversionCommon Stock, par value $0.001 per share | 10,000 | $2.80 | $28,000.00 |
DisclosureSEC source: 0001179110-16-029382 · edgar.xml · nonDerivative · entry 1 CATLIN AVERY W · CIK 0001255348 · Sr. VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,586 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.